A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

Phase 2

Recruiting

• Conditions: Parkinson Disease
• Interventions: Drug: AAV2-GDNF Gene therapy; Procedure: Control Surgery

• Registration Number: NCT06285643
• Lead Sponsor: AskBio Inc

Brief Summary

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-02-14
• Study First Submitted QC: 2024-02-23
• Study First Posted: 2024-02-29
• Study Start: 2024-06-11
• Status Verified: 2025-04
• Last Update Submitted: 2025-06-30
• Last Update Posted: 2025-07-01
• Primary Completion: 2027-11-30
• Study Completion: 2027-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

Age

1. Male and female adults 45-75 years of age inclusive, at the time of signing of informed consent Type of Subject and Disease Characteristics

2. Diagnosed with Parkinson's Disease in the past 4-10 years (inclusive) as defined by the following:

   1. Presence of bradykinesia PLUS any of the following:

      • Rigidity
      • Rest Tremor
      • Postural instability

   2. Presence of motor fluctuations as measured by the PD Motor Diary

   3. Stable anti-parkinsonian medication regiment for >/= 4 weeks prior to screening

   4. Must demonstrate responsiveness to levodopa therapy

Exclusion Criteria

• Known history or current evidence of medical, genetic, or neurological conditions that may provide an alternative to idiopathic PD diagnosis
• Presence or history of significant vascular and/or cardiovascular disease
• Presence of significant cognitive impairment, poorly controlled depression/anxiety
• Presence or history of psychosis or impulse control disorder
• History of malignancy other than treated cutaneous squamous or basal cell carcinomas
• Presence of clinically relevant conditions that could compromise surgical suitability and/or subject safety
• Contraindication to magnetic resonance imaging and/or use gadolinium-based contrast agents
• Prior history of brain surgery including, but no limited: DBS, pallidotomy focused ultrasound thalamotomy, or other experimental neurosurgical procedure
• Chronic immunosuppressive therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AAV2-GDNF	AAV2-GDNF Gene therapy	-
Control Surgery	Control Surgery	-

Primary Outcome Measures

Name	Time	Method
Change from baseline to Month 18 on PD Motor Diary	18 months	Normalized Good ON and OFF time per Hauser Diary

Trial Locations

Locations (39)

UCI Alpha Clinic (Neurology); 🇺🇸 Irvine, California, United States

Loma Linda University (Neurology); 🇺🇸 Loma Linda, California, United States

Loma Linda University (Surgical); 🇺🇸 Loma Linda, California, United States

University of California San Francisco (Neurology); 🇺🇸 San Francisco, California, United States

University of San Francisco (Surgical); 🇺🇸 San Francisco, California, United States

CenExel Rocky Mountain Clinical Research (Neurology); 🇺🇸 Englewood, Colorado, United States

Georgetown University (Neurology); 🇺🇸 Washington D.C., District of Columbia, United States

Parkinson's Disease and Movement Disorders Center of Boca Raton (Neurology); 🇺🇸 Boca Raton, Florida, United States

Parkinson's Disease Treatment Center of Southwest Florida (Neurology); 🇺🇸 Port Charlotte, Florida, United States

Emory University (Surgical); 🇺🇸 Atlanta, Georgia, United States

Scroll for more (29 remaining)